171 related articles for article (PubMed ID: 12465395)
1. Asian trends in prostate cancer hormone therapy.
Akaza H; Naito S; Cheng C; Kaisary A; Soebadi DM; Umbas R; Esuvaranathan K; Gu FL; Zhou L; Hong SJ; Kim WJ; Lee SE; Rim JS; Song JM; Yoon JH; Chang SJ; Huang CH; Yang CR; Hirao Y; Murai M; Tsukamoto T; Usami M
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1951-61. PubMed ID: 12465395
[TBL] [Abstract][Full Text] [Related]
2. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
[TBL] [Abstract][Full Text] [Related]
3. [Hormone therapy for prostate cancer].
Théodore C
Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
[TBL] [Abstract][Full Text] [Related]
4. [Trends of prostate cancer: comparison between 1986-90 and 1991-95 at Asahi General Hospital].
Tanaka M; Murakami S; Suzuki N; Oikawa T; Kinsui H; Hamano S; Shimazaki J
Hinyokika Kiyo; 1998 Nov; 44(11):775-80. PubMed ID: 9893221
[TBL] [Abstract][Full Text] [Related]
5. Changing demography of prostate cancer in Asia.
Sim HG; Cheng CW
Eur J Cancer; 2005 Apr; 41(6):834-45. PubMed ID: 15808953
[TBL] [Abstract][Full Text] [Related]
6. Advanced prostate cancer. Hormonal treatment.
de la Haba-RodrÃguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
7. The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
Akaza H; Naito S; Chang SJ; Chen KK; Cheng C; Choi HY; Fujioka T; Hinotsu S; Hirao Y; Hong SJ; Kim CS; Kim WJ; Lee SE; Murai M; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Xia S; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1285-95. PubMed ID: 15332559
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
9. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
10. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
Akaza H; Hirao Y; Labrie F; Soloway MS
Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
[TBL] [Abstract][Full Text] [Related]
11. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
13. The 2nd conference on Asian trends in prostate cancer hormone therapy.
Akaza H; Chang SJ; Chen KK; Esuvaranathan K; Fujioka T; Hirao Y; Hong SJ; Hinotsu S; Kim WJ; Lau W; Lee SE; Murai M; Naito S; Ogawa O; Rim JS; Soebadi DM; Song JM; Tsukamoto T; Umbas R; Usami M; Yang CR; Yoon JH; Zhou L
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1533-42. PubMed ID: 14584292
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.
Akaza H; Usami M; Hinotsu S; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Hirao Y; Murai M; Yamanaka H
Jpn J Clin Oncol; 2004 Jun; 34(6):329-36. PubMed ID: 15333685
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Working Group report.
Namiki M; Akaza H; Lee SE; Song JM; Umbas R; Zhou L; Lee BC; Cheng C; Chung MK; Fukagai T; Hinotsu S; Horie S
Jpn J Clin Oncol; 2010 Sep; 40 Suppl 1():i70-75. PubMed ID: 20870924
[TBL] [Abstract][Full Text] [Related]
16. [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation].
Akaza H; Labrie F; Namiki M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):657-69. PubMed ID: 17431361
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.
Oefelein MG; Agarwal PK; Resnick MI
J Urol; 2004 Apr; 171(4):1525-8. PubMed ID: 15017212
[TBL] [Abstract][Full Text] [Related]
18. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
19. Re: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
Vikram B
J Natl Cancer Inst; 2006 Dec; 98(24):1826; author reply 1826. PubMed ID: 17179485
[No Abstract] [Full Text] [Related]
20. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.
Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM
J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]